Pfizer, on Tuesday, said it will begin testing its COVID-19 vaccine on children under age 12. This will encompass selecting a lower dose of the shot in an earlier stage of the trial. According to Pfizer, the study will enroll almost 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain.

Pfizer said it will test 10 micrograms of dose on children aged between 5-11; 3 micrograms for the age group of 6 months to 5. The amount of dosage was ascertained by safety, tolerability and the immune response that was shown by 144 children in a phase I study of the two-dose shot.

As per a Reuters reports, the company spokesperson said it expects data from children aged 5 to 11 in September and will be aiming to ask the regulators for emergency use authorization later that month.

Pfizer is expected to have its data from the 6-month to 2-year-old age group sometime in October or November.

Earlier, the Pfizer vaccine was authorised for use for children aged 12 in Europe, the United States and Canada. The 12-year-olds receive the same dosage as the adults i.e 30 micrograms.

To date, USCDC has said that nearly 7 million teens have received at least one dose of the vaccine.